BZL Biologics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 (NCT00040586) | BZL Biologics |
Track BZL Biologics automatically
Every clearance here is in the API, with alerts when new ones post.